Quantitative Estimation of Osteoprotegerin biomarker of Metabolic Syndrome Patients in Najaf city, Iraq

Abstract

Objective: The prime objective of this investigation was to find a new method for the diagnosis of Metabolic Syndrome disease (MetS) by estimating the level of Osteoprotegerin (OPG) in the serum of patients. Subjects and Methods: The study included 106 subjects divided into two groups, (61) with Metabolic Syndrome and (45) in the control group, the mean of its age was 50. Most of the serum assays were measured by colourimetric methods, and ELISA Technique evaluated serum levels of OPG. Results: The clinical findings confirm that OPG is expressed in cells involved in atheroma plaque development and progression, such as arterial smooth muscle cells these leads showed that OPG levels were more elevated compared to the levels of the control group (p < 0.00001). Others outcomes the Pearson's correlation study illustrated that the OPG level is positive relationships with fasting blood glucose (FBG) and Hemoglobin A1C (HBA1C) (r = 0.919, p < 0.00001), (r = 0.628, P=0.002) respectively. Also, strong positively correlation with insulin level and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (r = 0.759, p = 0.010) (r = 0.628, P< 0.00001) respectively. Furthermore, the OPG level denoted a significant positive correlation with the obesity index is the ratio of waist circumference to hip circumference (WHR) (r =0.594, P< 0.00001) and Triglycerides (TG) (r =0.475, P< 0.00001). Conclusion: These results support a strong correlation between serum OPG level and most indicators of metabolic syndrome disease, so we can conclude that it is a great biomarker for predicting Metabolic Syndrome disease (MetS) in individuals who are likely to be infected with this disease, such as hypertension patients and obese people.